Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

Full text
Author(s):
Buhmann, R. [1, 2] ; Simoes, B. [2] ; Stanglmaier, M. [3] ; Yang, T. [2] ; Faltin, M. [3] ; Bund, D. [2] ; Lindhofer, H. [4] ; Kolb, H-J [2]
Total Authors: 8
Affiliation:
[1] Univ Munich Grosshadern, Dept Med 3, Helmholtz Ctr Munich, CCG HCT, D-81377 Munich - Germany
[2] German Res Ctr Environm Hlth GmbH, Helmholtz Ctr Munich, CCG HCT, Munich - Germany
[3] TRION Res GmbH, Martinsried - Germany
[4] TRION Pharma GmbH, Munich - Germany
Total Affiliations: 4
Document type: Journal article
Source: BONE MARROW TRANSPLANTATION; v. 43, n. 5, p. 383-397, MAR 2009.
Web of Science Citations: 35
Abstract

Donor lymphocyte infusions (DLIs) after allo-SCT displayed limited use in CLL and highly malignant non-Hodgkin's lymphoma (NHL). Here we studied whether Bi20 (FBTA05), a novel trifunctional bispecific antibody targeting CD20 on lymphoma cells and CD3 on T cells, could induce GVL responses in combination with DLI or mobilized PBSCT after allogeneic transplantation in these diseases. Six patients (three cases with p53-mutated CLL and three with high-grade NHL (HG-NHL)) refractory to standard therapy were treated with escalating doses of Bi20 (range 10-2000 mu g) followed by DLI or SCT. Thereby, all CLL patients showed a prompt but transient clinical and hematological response. In one patient with HG-NHL, we observed a halt in progression for almost 4 months. Side effects (fever, chills and bone pain) were tolerable and appeared at antibody dose levels between 40 and 200 mu g. The cytokine pro. le was characterized by transient increases of IL-6, IL-8 and IL-10. Neither human anti-mouse antibodies nor GVHD developed, allowing repeated treatment courses. In summary, the trifunctional antibody Bi20 induced prompt antitumor responses in extensively pretreated, p53-mutated alemtuzumab and rituximab refractory patients indicating its therapeutic potential. (AU)

FAPESP's process: 01/04492-8 - Cancer immunotherapy: the indolent B-cell malignancies as a tumor model
Grantee:Belinda Pinto Simoes
Support Opportunities: Scholarships abroad - Research